The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer
Open accessAbstract
BACKGROUND: Dostarlimab is an immune-checkpoint inhibitor that targets the programmed cell death 1 receptor. The combination of chemotherapy and immunotherapy may have synergistic effects in the treatment of endometrial cancer. METHODS: We conducted a phase 3, global, double-blind, randomized, placebo-controlled trial. Eligible patients with primary advanced stage III or IV or first recurrent endometrial cancer were randomly assigned in a 1:1 ratio to receive either dostarlimab (500 mg) or placebo, plus carboplatin (area under the concentration-time curve, 5 mg per milliliter per minute) and paclitaxel (175 mg per square meter of body-surface area), every 3 weeks (six cycles), followed by dostarlimab (1000 mg) or placebo every 6 weeks for up to 3 years. The primary end points were progression-free survival as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, and overall survival. Safety was also assessed. RESULTS: Of the 494 patients who underwent randomization, 118 (23.9%) had mismatch repair-deficient (dMMR), microsatellite instability-high (MSI-H) tumors. In the dMMR-MSI-H population, estimated progression-free survival at 24 months was 61.4% (95% confidence interval [CI], 46.3 to 73.4) in the dostarlimab group and 15.7% (95% CI, 7.2 to 27.0) in the placebo group (hazard ratio for progression or death, 0.28; 95% CI, 0.16 to 0.50; P<0.001). In the overall population, progression-free survival at 24 months was 36.1% (95% CI, 29.3 to 42.9) in the dostarlimab group and 18.1% (95% CI, 13.0 to 23.9) in the placebo group (hazard ratio, 0.64; 95% CI, 0.51 to 0.80; P<0.001). Overall survival at 24 months was 71.3% (95% CI, 64.5 to 77.1) with dostarlimab and 56.0% (95% CI, 48.9 to 62.5) with placebo (hazard ratio for death, 0.64; 95% CI, 0.46 to 0.87). The most common adverse events that occurred or worsened during treatment were nausea (53.9% of the patients in the dostarlimab group and 45.9% of those in the placebo group), alopecia (53.5% and 50.0%), and fatigue (51.9% and 54.5%). Severe and serious adverse events were more frequent in the dostarlimab group than in the placebo group. CONCLUSIONS: Dostarlimab plus carboplatin-paclitaxel significantly increased progression-free survival among patients with primary advanced or recurrent endometrial cancer, with a substantial benefit in the dMMR-MSI-H population. (Funded by GSK; RUBY ClinicalTrials.gov number, NCT03981796.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21708 · Cited by 17,196
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733
First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer
Horn, L., Mansfield, A. S., Szczęsna, A., Havel, L., Krzakowski, M., Hochmair, M. J., Huemer, F., Losonczy, G., Johnson, M. L., Nishio, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809064 · Cited by 3,586
Janjigian, Y. Y., Shitara, K., Moehler, M., Garrido, M., Salman, P., Shen, L., Wyrwicz, L., Yamaguchi, K., Skoczylas, T., Campos Bragagnoli, A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00797-2 · Cited by 3,041
Paz-Ares, L., Dvorkin, M., Chen, Y., Reinmuth, N., Hotta, K., Trukhin, D., Statsenko, G., Hochmair, M. J., Özgüroğlu, M., Ji, J. H., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32222-6 · Cited by 2,298
ESGO/ESTRO/ESP Guidelines for the Management of Patients with Endometrial Carcinoma
Concin, N., Matias-Guiu, X., Vergote, I., Cibula, D., Mirza, M. R., Marnitz, S., Ledermann, J., Bosse, T., Chargari, C., Fagotti, A., et al. (2021) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2020-002230 · Cited by 1,989
Self-citationLandscape of Microsatellite Instability Across 39 Cancer Types
Bonneville, R., Krook, M. A., Kautto, E. A., Miya, J., Wing, M. R., Chen, H.-Z., Reeser, J. W., Yu, L., & Roychowdhury, S. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00073 · Cited by 1,476
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer
Cortes, J., Rugo, H. S., Cescon, D. W., Im, S.-A., Yusof, M. M., Gallardo, C., Lipatov, O., Barrios, C. H., Perez-Garcia, J., Iwata, H., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2202809 · Cited by 1,192
Luchini, C., Bibeau, F., Ligtenberg, M. J. L., Singh, N., Nottegar, A., Bosse, T., Miller, R., Riaz, N., Douillard, J.-Y., Andre, F., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz116 · Cited by 1,041
Microsatellite Instability as a Biomarker for PD-1 Blockade
Dudley, J. C., Lin, M.-T., Le, D. T., & Eshleman, J. R. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1678 · Cited by 931
The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies
Emens, L. A., & Middleton, G. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0064 · Cited by 831
Lu, K. H., & Broaddus, R. R. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1514010 · Cited by 663
Mehra, R., Seiwert, T. Y., Gupta, S., Weiss, J., Gluck, I., Eder, J. P., Burtness, B., Tahara, M., Keam, B., Kang, H., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0131-9 · Cited by 454
Molecular Pathways: The Immunogenic Effects of Platinum-Based Chemotherapeutics
Hato, S. V., Khong, A., de Vries, I. J. M., & Lesterhuis, W. J. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3141 · Cited by 451
Oaknin, A., Tinker, A. V., Gilbert, L., Samouëlian, V., Mathews, C., Brown, J., Barretina-Ginesta, M.-P., Moreno, V., Gravina, A., Abdeddaim, C., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.4515 · Cited by 364
Self-citationMiller, D. S., Filiaci, V. L., Mannel, R. S., Cohn, D. E., Matsumoto, T., Tewari, K. S., DiSilvestro, P., Pearl, M. L., Argenta, P. A., Powell, M. A., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01076 · Cited by 351
Self-citationOaknin, A., Gilbert, L., Tinker, A. V., Brown, J., Mathews, C., Press, J., Sabatier, R., O’Malley, D. M., Samouelian, V., Boni, V., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003777 · Cited by 338
Self-citationGu, B., Shang, X., Yan, M., Li, X., Wang, W., Wang, Q., & Zhang, C. (2021) · Gynecologic Oncology · doi:10.1016/j.ygyno.2021.01.036 · Cited by 326
Sevko, A., Michels, T., Vrohlings, M., Umansky, L., Beckhove, P., Kato, M., Shurin, G. V., Shurin, M. R., & Umansky, V. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202781 · Cited by 246
The Immune Biology of Microsatellite-Unstable Cancer
Kloor, M., & von Knebel Doeberitz, M. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.02.004 · Cited by 245
Opzoomer, J. W., Sosnowska, D., Anstee, J. E., Spicer, J. F., & Arnold, J. N. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01654 · Cited by 160
Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice
Pfannenstiel, L. W., Lam, S. S. K., Emens, L. A., Jaffee, E. M., & Armstrong, T. D. (2010) · Cellular Immunology · doi:10.1016/j.cellimm.2010.03.001 · Cited by 159
TCGA Molecular Prognostic Groups of Endometrial Carcinoma: Current Knowledge and Future Perspectives
Arciuolo, D., Travaglino, A., Raffone, A., Raimondo, D., Santoro, A., Russo, D., Varricchio, S., Casadio, P., Inzani, F. S., Seracchioli, R., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911684 · Cited by 121
The Changing Landscape of Gynecologic Cancer Mortality in the United States
Giaquinto, A. N., Broaddus, R. R., Jemal, A., & Siegel, R. L. (2022) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000004676 · Cited by 107
Lorusso, D., Ferrandina, G., Colombo, N., Pignata, S., Pietragalla, A., Sonetto, C., Pisano, C., Lapresa, M., Savarese, A., Tagliaferri, P., et al. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.10.013 · Cited by 101
Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy
Viale, G., Trapani, D., & Curigliano, G. (2017) · BioMed Research International · doi:10.1155/2017/4719194 · Cited by 90
Sorbe, B., ANDERSSON, H., Boman, K., Rosenberg, P., & Kalling, M. (2007) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2007.01094.x · Cited by 89
Current Approaches to the Management of Patients with Endometrial Cancer
Kalampokas, E., Giannis, G., Kalampokas, T., Papathanasiou, A.-A., Mitsopoulou, D., Tsironi, E. E., Triantafyllidou, O., Gurumurthy, M., Parkin, D. E., Cairns, M. R., et al. (2022) · Cancers · doi:10.3390/cancers14184500 · Cited by 74
Liechtenstein, T., Pérez‐Janices, N., Gato, M., Caliendo, F., Kochan, G. T., Blanco‐Luquin, I., der Jeught, K. V., Vargas, F. A., Guerrero‐Setas, D., Fernández‐Irigoyen, J., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2279 · Cited by 71
Seligson, N. D., Knepper, T. C., Ragg, S., & Walko, C. M. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1946 · Cited by 66
Fountzilas, E., Kotoula, V., Pentheroudakis, G. E., Manousou, K., Polychronidou, G., Vrettou, E., Poulios, C., Papadopoulou, E., Raptou, G., Pectasides, E., et al. (2019) · ESMO Open · doi:10.1136/esmoopen-2018-000474 · Cited by 58
Memory and other properties of multiple test procedures generated by entangled graphs
Maurer, W., & Bretz, F. (2012) · Statistics in Medicine · doi:10.1002/sim.5711 · Cited by 26
Cited by
Siegel, R. L., Giaquinto, A. N., & Jemal, A. (2024) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21820 · Cited by 9,533
FIGO staging of endometrial cancer: 2023
Berek, J. S., Matias‐Guiu, X., Creutzberg, C., Fotopoulou, C., Gaffney, D., Kehoe, S., Lindemann, K., Mutch, D., Concin, N., & Endometrial Cancer Staging Subcommittee, F. W. C. C. (2023) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.14923 · Cited by 1,000
Westin, S. N., Moore, K., Chon, H. S., Lee, J.-Y., Thomes Pepin, J., Sundborg, M., Shai, A., de la Garza, J., Nishio, S., Gold, M. A., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02132 · Cited by 380
Self-citationFIGO staging of endometrial cancer: 2023
Berek, J. S., Matias-Guiu, X., Creutzberg, C., Fotopoulou, C., Gaffney, D., Kehoe, S., Lindemann, K., Mutch, D., Concin, N., & Endometrial Cancer Staging Subcommittee, F. W. C. C. (2023) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2023.34.e85 · Cited by 262
Cancer treatment and survivorship statistics, 2025
Wagle, N. S., Nogueira, L., Devasia, T. P., Mariotto, A. B., Yabroff, K. R., Islami, F., Jemal, A., Alteri, R., Ganz, P. A., & Siegel, R. L. (2025) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.70011 · Cited by 261
Metadata
- Authors
- Mirza, M. R., Chase, D. M., Slomovitz, B. M., dePont Christensen, R., Novák, Z., Black, D., Gilbert, L., Sharma, S., Valabrega, G., Landrum, L. M., Hanker, L. C., Stuckey, A., Boere, I., Gold, M. A., Auranen, A., Pothuri, B., Cibula, D., McCourt, C., Raspagliesi, F., Shahin, M. S., Gill, S. E., Monk, B. J., Buscema, J., Herzog, T. J., Copeland, L. J., Tian, M., He, Z., Stevens, S., Zografos, E., Coleman, R. L., & Powell, M. A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-06-08
- Volume
- 388
- Issue
- 23
- Pages
- 2145-2158
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4360991857
- Cited by
- 862
- References
- 35
- FWCI
- 236.19
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.